US Appeals court overturns Copaxone patents, while UK comes out in Teva's favor
This article was originally published in Scrip
Executive Summary
Momenta Pharmaceuticals/Sandoz and Mylan Laboratories/Natco Pharmaceuticals can now plan to start selling generic Copaxone in May 2014 in the US market, around 18 months sooner than previously slated, after a federal appeals court declared several of the patents protecting Teva's multiple sclerosis drug to be invalid for being "indefinite" on 26 July.